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BRAF and MC1R in Melanoma:
Different in Head and Neck Tumors?
Emma C. Fink1 and David E. Fisher1
In this issue, Hacker et al. (2013) report the largest study to date on the association
between MC1R variants and BRAF mutant melanoma. Although they did not
observe a significant overall correlation, there was a significant negative
association between BRAF and MC1R mutations for head/neck melanomas. This
suggests a fundamental difference in pathogenesis between head/neck and
truncal melanomas, which could contribute to their divergent prognoses.
Journal of Investigative Dermatology (2013) 133, 878–880. doi:10.1038/jid.2012.475
Cutaneous melanoma arises from com-
plex interactions among genetic and
environmental factors. Epidemiological
and molecular evidence indicates that
these interactions may influence not only
the incidence of melanomas but also
their fundamental pathogenic mechan-
isms. A high fraction of cutaneous mela-
nomas have acquired somatic mutations
in BRAF or NRAS, but these muta-
tions are generally mutually exclu-
sive. Mutations in both BRAF and NRAS
lead to extracellular signal–regulated
kinase activation, enhancing prolifera-
tion, survival, and invasion (Thomas,
2006). However, the presence of signi-
ficant gene expression and signaling-
related differences suggests that BRAF
and NRAS mutations utilize at least
partially distinct mechanisms of melano-
genesis (Bloethner et al., 2005).
BRAF is a serine/threonine kinase
involved in the Ras–RAF–mitogen-acti-
vated protein kinase pathway. Mutations
See related article on pg 1027
in BRAF are found in approximately
50% of cutaneous melanomas, most
often those that arise on intermittently
sun-exposed skin in relatively young
patients (Thomas, 2006; Tsao et al.,
2012). Although over 30 different
BRAF mutations have been reported,
one mutation, BRAF V600E, is by far
the most common. Although UV
exposure is a major risk factor for
melanoma, BRAF V600E is due to an
T-A transversion, rather than the more
commonly UV-associated C-T
transition (Brash, 1997; Tsao et al.,
2012). Some have suggested that
selection of rare UV-induced C-T
transitions could explain this
observation; others posit that the
reactive oxygen species (ROS)
generated as a by-product of melanin
synthesis are a more likely culprit
(Thomas, 2006).
Melanoma risk is strongly tied to
pigmentation, a key determinant of
which is MC1R. MC1R is an as-type G
protein–coupled receptor, which is
found on melanocytes and which
responds to a-melanocyte-stimulating
hormone. MC1R is highly polymorphic
in Caucasians with over 60 variants,
classified as partial loss of function
(r alleles) or complete loss of function
(R alleles) (Garcia-Borron et al., 2005;
Tsao et al., 2012). Polymorphisms in
MC1R contribute to the phenotypic
spectrum of freckling and hair and skin
coloration (particularly red hair), but
have also been suggested to modulate
melanoma risk independent of
pigmentation. Cells expressing MC1R
variants have higher levels of ROS,
which could potentially contribute to
ROS-related BRAF mutations (Thomas,
2006; Tsao et al., 2012). Our group
recently demonstrated a UV-
independent increase in oxidative lipid
and DNA damage in a ‘‘redhead’’
mouse model with inactive MC1R.
Expression of BRAF V600E in this
model led to an increased risk of
invasive melanoma in the absence of
providing secondary mutations or UV
exposure. Both oxidative damage and
melanoma development were abrogated
when pigment production was blocked
by an albino allele, suggesting that
pheomelanin production is key to
these phenotypes (Mitra et al., 2012).
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Previous work
The link between MC1R variants and
BRAF in clinical melanoma specimens
has been investigated in several different
cohorts, with variable results. In this issue,
Hacker et al. (2013) present the largest
study to date. Landi et al. (2006) first
reported an association between germ-
line MC1R mutations and somatic BRAF
melanoma mutations in two independent
Italian cohorts of 85 and 112 patients.
BRAF mutations were 6–12 times more
frequent in patients with at least one
variant MC1R allele, relative to patients
with two copies of wild-type MC1R. This
association was stronger in younger
patients and additional BRAF mutant
tumors explained the entire 3.3-fold over-
all increased melanoma risk in patients
with MC1R variants. These findings were
replicated in an independent Italian popu-
lation (165 patients) by Fargnoli et al.
(2008), who found that MC1R vari-
ants increased melanoma risk by a factor
of 2.2 (95% confidence interval (CI) 1.4–
3.4). This increased overall risk could be
explained entirely by an increased suscep-
tibility to BRAF mutant melanomas, which
were 5 to 15-fold more common in
patients with at least one MC1R variant
allele (P-value o0.0001). However,
neither Thomas et al. (2010) nor Hacker
et al. (2010) found a significant associa-
tion between MC1R mutations and BRAF
mutant melanomas in 219 patients
in North Carolina or 123 Australian
patients, respectively. In an additional
study, Scherer et al. (2010) reported a
significant correlation between MC1R and
BRAF status in 202 paraffin-embedded
samples, but their inverse association
was in the opposite direction from the
positive correlations reported by Landi
et al. (2006) and Fargnoli et al. (2008).
In the Scherer study, patients with MC1R
variants were less likely to have BRAF
mutant tumors (odds ratio (OR)¼0.24,
95% CI 0.09–0.6, P-value¼ 0.001), but
this effect was driven by cases of nodular
melanoma (OR¼0.11, 95% CI 0.03–
0.43); there was no significant interaction
for any other histotype (Scherer et al.,
2010). Thus, before Hacker et al. (2013),
two studies reported a positive association
between genomic MC1R mutations and
somatic BRAF mutations, two studies
reported no correlation, and one
study reported a histotype-dependent
association.
Are head and neck melanomas different?
Hacker et al. (2013) investigated this
question in the largest cohort to date:
134 Spanish and 241 Austrian patients.
For melanomas of the trunk, they obser-
ved a nonsignificant trend toward a posi-
tive association between MC1R variant
status and the presence of somatic
BRAF mutations (OR¼ 1.8, CI 0.8–4.1,
P-value¼0.1). However, they also found
a significant negative association between
MC1R variants and BRAF for head and
neck melanomas (OR¼0.3, CI 0.1–0.8,
P-value¼0.02). Head and neck
melanomas are often nodular, and thus
this result is consistent with the findings of
Scherer et al. (2010). The authors also
assessed NRAS mutation status. Relative to
BRAF mutations, NRAS mutations were
more common in older patients and in
patients with evidence of significant sun
exposure (the presence of solar keratoses).
It is not clear why these studies show
varied relationships between oncogene
incidences and MC1R. The frequency of
specific MC1R mutations, the presence
of modifying alleles, and environmental
differences between the populations
may contribute to this variability. In
these studies, MC1R variants conferred
an increased overall risk of melanoma,
and perhaps a slight increase in the risk
of BRAF mutant melanoma. However,
the trends of association between MC1R
and BRAF were dependent on anatomic
location: for the trunk, patients with
MC1R variants had a higher proportion
of BRAF-positive tumors; for the head
and neck, they had a lower proportion.
This suggests that the pathogenesis of
head and neck melanomas differs from
that of truncal melanomas. This is a
potentially important point, because
the clinical behavior of these melano-
mas may also vary. Head and neck
melanomas often have nodular histol-
ogy, which is diagnosed at a deeper
stage, and is correspondingly associated
with worsened prognosis.
In conclusion, the role of UV expo-
sure in melanogenesis may vary by
anatomic site, MC1R variant status,
and the oncogene constellation of the
tumor. Although it may be tempting to
speculate that varied MC1R status or UV
exposure may participate in the muta-
tional events that generate mutant BRAF
or NRAS, it is also plausible that differ-
ent rate-limiting oncogenic mutations
are the targets of MC1R and UV, and
must become mutated in order for an
invasive melanoma to form. Understand-
ing the cellular and molecular interplay
between MC1R variants, UV stress, and
BRAF/NRAS mutations could provide
important insight into the pathogenesis
of various types of melanoma and how
they may be prevented or treated.
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Clinical Implications
 This study found no significant overall correlation between MC1R germ-
line mutations and BRAF mutant melanomas.
 There was a significant negative association between MC1R and BRAF
mutations in head and neck melanomas.
 This suggests that the pathogenesis of head and neck melanomas may
differ from truncal melanomas.
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